Research analysts at BMO Capital Markets initiated coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research report issued on Thursday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $78.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 19.02% from the stock’s current price.
Several other brokerages have also recently weighed in on GILD. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Saturday, December 1st. BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, December 4th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, November 14th. Oppenheimer restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, November 14th. Finally, Citigroup restated a “buy” rating and issued a $100.00 price objective on shares of Gilead Sciences in a report on Tuesday, February 5th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $81.52.
GILD stock traded up $0.74 during trading hours on Thursday, reaching $65.54. 6,449,203 shares of the stock were exchanged, compared to its average volume of 7,522,282. The stock has a market cap of $82.69 billion, a PE ratio of 10.66, a price-to-earnings-growth ratio of 4.08 and a beta of 1.16. The company has a current ratio of 3.38, a quick ratio of 3.29 and a debt-to-equity ratio of 1.19. Gilead Sciences has a 12 month low of $60.32 and a 12 month high of $80.90.
In other Gilead Sciences news, Director Gayle E. Wilson sold 19,068 shares of the firm’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the completion of the sale, the director now directly owns 143,567 shares in the company, valued at $9,630,474.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.16% of the company’s stock.
A number of hedge funds have recently modified their holdings of GILD. Athena Capital Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $27,000. Capital Financial Planning LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $27,000. Advisors Preferred LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $31,000. Legacy Financial Advisors Inc. raised its position in shares of Gilead Sciences by 361.3% in the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 383 shares in the last quarter. Finally, Claybrook Capital LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 78.23% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.